학술논문

Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feasibility, efficacy and molecular predictors.
Document Type
Academic Journal
Source
Hematological Oncology (HEMATOL ONCOL), Jun2023 Supplement 1; 41: 424-425. (2p)
Subject
Language
English
ISSN
0278-0232